Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Merck
Boehringer Ingelheim
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR NIMOTOP


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nimotop

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00781326 ↗ Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression Terminated National Institute of Mental Health (NIMH) Phase 4 2008-08-01 This study will examine whether combined use of an antidepressant medication and the medication nimodipine reduces risk of depression relapse in patients with vascular depression.
NCT00781326 ↗ Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression Terminated University of Pittsburgh Phase 4 2008-08-01 This study will examine whether combined use of an antidepressant medication and the medication nimodipine reduces risk of depression relapse in patients with vascular depression.
NCT01551368 ↗ Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients Terminated Mount Sinai Hospital, Canada Phase 2 2012-12-01 Nimodipine (NimotopĀ® Bayer Pharmaceuticals Corporation), unlike other calcium channel blockers is fat soluble and therefore is able to cross the blood-brain barrier1. Gonadotropin releasing hormone (GnRH) neurons are clustered in the hypothalamus and are dependent on calcium flux to release GnRH responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. In a natural menstrual cycle a spontaneous LH surge occurs mid-cycle which triggers ovulation. The investigators hypothesized that nimodipine, by blocking calcium channels, may effectively suppress the release of GnRH and consequently the natural LH surge. In this prospective double-blinded randomized study the investigators will evaluate the efficacy of nimodipine to inhibit the natural LH surge in women undergoing controlled ovarian stimulation (COS) and intrauterine insemination (IUI). Nimodipine, if successful, may represent an inexpensive oral medication as an alternative to the currently used GnRH agonists or GnRH antagonists in assisted reproductive technologies like IVF.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nimotop

Condition Name

Condition Name for Nimotop
Intervention Trials
Depression 2
Electroconvulsive Therapy 1
Vestibular Schwannoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nimotop
Intervention Trials
Infertility 2
Depression 2
Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nimotop

Trials by Country

Trials by Country for Nimotop
Location Trials
United States 3
Canada 2
China 1
Austria 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nimotop
Location Trials
California 1
Massachusetts 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nimotop

Clinical Trial Phase

Clinical Trial Phase for Nimotop
Clinical Trial Phase Trials
Phase 4 1
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nimotop
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nimotop

Sponsor Name

Sponsor Name for Nimotop
Sponsor Trials
University of Pittsburgh 1
Amsterdam University Medical Center 1
Mount Sinai Hospital, Canada 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nimotop
Sponsor Trials
Other 15
Industry 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.